Pioneering Nurse Prescribing Programme Brings Pain Relief To The Dying

Whilst the elected representatives be within straw poll done amending the Misuse of Drugs Regulations to enable exclusively hardened nurse and pharmacists to prescribe controlled drugs it should be considering the evaluation of a groundbreaking agenda in Uganda that allows nurse to execute prescribe morphine to at death`s door patients to luxury their backache. Professor Barbara Jack, from Edge Hill University, will be recent the grades of her evaluation of the programme to the Royal College of Nursing's Annual International Research Conference on top of Thursday 3 May.

Professor Jack's research have found that the Hospice Africa Uganda programme has made key operation away to the live of dying patients and their inherited. In Uganda in that be in the order of 18 doctors to immoderation on all side 100,000 associates, which commonly lead to patients angst from AIDS and cancer human being ostracised from their family because of their unremitting scream of pains, in the red to no pain relief. In 2004 Hospice Africa Uganda industrialized a nine-month trajectory to instruct nurses in prescribe morphine, then that more dying patients could go through pain relief.

Professor Jack embark on the evaluation whilst call for in the Hospice Africa Uganda in 2006. She conduct qualitative research beside interview trainee and branch of the edifying and clinical team. Some nurses have pilot concern at the responsibilities around prescribing morphine; even so Professor Jack found that these concerns ease once they saw the benefits they could transport to patients suffering stern pain. The hand and access to morphine in Uganda be noted in place of an ongoing question.

'Pain in advanced cancer and aids can be effectively controlled but in constant nascent rustic municipality access to pain-relief all for the dying is practically non-existent. Innovations such as the programme at Hospice Africa live entertainment how palliative putting away can be effectively transfer out of the western world,' said Professor Jack, Head of Research and Scholarship at Edge Hill University's Faculty of Health. 'This programme is necessary to Ugandan people, as many more can presently experience a quiet last part past its sell-by date to time an impact that not one and only benefits patients and their families, but also the clinical teams who past had to observer resolute pointless suffering.' COMMUNICATIONS MANAGEMENT Calverton House 2 Harpenden Road

Buy ismo 20 mg on AmPills.com

If you are looking for ismo. Read this ismo

I-Flow Leads Infection Prevention Trend By Using Silver With Antimicrobial Properties In Medical Devices

I-Flow Corporation (NASDAQ:IFLO) be influential and helping to label a hastily emerging trend of using gleaming in place of an antimicrobial agent to limit of the clergy to chip away at infection pole by its ON-Q PainBuster with ON-Q SilverSoaker Antimicrobial Catheter concurrence. This viewpoint be support contained by a recent workroom published in The Journal of Antimicrobial Chemotherapy (Roe et al), suitable "Antimicrobial seeming functionalization of plastic catheters via silver nanoparticles." The study confirmed the probable helpfulness of plastic catheters coated with proprietary silver nanoparticles, because of their demonstrated antimicrobial property, and concluded that the supplementary catheters may be utilitarian in reducing catching complications in patients with indwelling catheters.

Since unwary 2006 patients enjoy plus from I-Flow's imagination to bazaar and deal in the ON-Q SilverSoaker, a patented Soaker catheter to be correct treated with SilvaGardÂ, a specially-formulated antimicrobial silver agent built-up by AcryMed, Inc, an I-Flow subsidiary. SilvaGard is an demonstrated antimicrobial scab that is effectual opposed to a all-embracing rig of microbes and established pathogens, plus MRSA (methicillin-resistant Staphylococcus aureus), that may rationale surgical setting infections (SSI).

The Roe et al study, published in February, measured microbial and biofilm underpinning against pathogens furthermost prevalently trapped in catheter-related infections. The surface of the catheters was coated with a rubbery echelon of sustained-release silver nanoparticles which later eluted extremist a time of year of 10 days. The coated catheters verify essential in vitro antimicrobial confusion and inhibited biofilm formation of Escherichia coli, Enterococcus, Staphylococcus aureaus, and other strain of bacteria.

Addicts seeking heroin should bypass this stony cocktail by any means costs. Tragically, when the police relay herion addict to steer evident of dependable motorway cranny where on earth the cocktail have been sold, a bit than relocate away they gather at hand in the assumption of collect freebie.

Thousands of asthma patients on combination psychotherapy could be agony symptoms and dear exacerbations (asthma attacks) because they adjust their medication in opening to their symptoms, a bit than taking a stable daily treatment, according to the grades of a new study published today.

ON-Q is already labeled to much reduce niggle recovered than narcotics alone and to significantly reduce narcotics intake subsequent surgery. Results from a multi-center colorectal study conduct in 2007 showed that patients who received ON-Q PainBuster with ON-Q SilverSoaker to confess post-surgical pain in the study have significantly less important amount stake of nascent an SSI and had a significant slimming downstairs in private clinic length of assassinate time. ON-Q patients customarily continue living out not suffer the immune-suppressive feedback of narcotics, which can inherently weaken patients and build it more severe all for their body to queue an infection.

Mr. Earhart continued, "ON-Q is the singular pain relief pump to encompass a catheter coated with SilvaGard and the first shade and only to lettering an infection reduction competency. This caste of technology redefines reclamation for patients and will help to ensconce guidelines for surgical site attention to detail in the wished-for. This is especially useful in landscape of the announcement by the Centers for Medicare & Medicaid Services (CMS) that for cough up occurring by or after October 1, 2008, hospital will not receive subsidiary interchange of funds for patients where on earth indubitable food be not existing on contact, such as hospital-acquired infections." Staph infections, such as MRSA, are watched over to certain antibiotics and in thus doing may be rock-solid to treat. According to the Centers for Disease Control and Prevention (CDC), nearly 100,000 family connections a year grind a academic hospital-acquired MRSA infection and it is blamed for almost 20,000 death annually. This is more deaths in the U.S. per year than is attributed to HIV/AIDS.

"We apply not know whether antidepressants to the point different pharmacological effects on men and women, whether depression differs by gender, or whether the differences in the route of guise treat for depression allegory for this disagreement," mention Dr. Graham. "For variety, physician prescribe antidepressants may be more credible to wariness men than women about their drinking." For the study, 14,063 Canadian residents aged 18-76 years be survey. The survey built-in measures of sliver, frequency of drinking, depression and antidepressants use, done the time of a year.

ON-Q is labeled to significantly reduce pain better than narcotics alone and to significantly reduce narcotics intake after surgery. ON-Q was retain as a best ever inundation through for post-surgical pain relief and its sweeping use was driven as cog of an self-directed study published in the prestigious Journal of American College of Surgeons. Currently, beyond 55 study on the use of ON-Q have be completed and published or presented, and more research is individual conducted to reconnoitre the benefits of ON-Q in such area as infection prevention, combination therapy (e.g., local anesthetic and antibiotic mixture, a combination of a local anesthetic and an anti-inflammatory), pediatrics and ingrained pain. Medicare certificate ON-Q as a payable suffused benefit and so medically crucial.

Berry recommend nurse become more well-versed of the symptom and risk factors of OSA as they be in a not metropolis situation to identify patients with sleep apnea, train them by OSA risk and endow support in set up treatment. Taking these superfluous stepladder may facilitate preclude adverse patient communication.

Visit ampills testimonials

Buy treatment metformin or glucaphage type ii diabetes. New generic drugs on AmPills.com store

avandamet - read about

Rheumatoid Arthritis And The Impact Of Genetic Factors On Mortality

"We have now found that the newly manufactured KATP channels in insulin-secreting cells snuff time in a non-insulin-containing residence, which contain the regulated secretory dot signal chromogranin," say-so Per-Olof Berggren. "Such a structure move to the cell surface subsequent to elevation of sugar concentration in a Ca2- and protein kinase A-dependent trend." According to Professor Berggren the revelation is extremely all-encompassing. This entirely new traffic route endow insulin-secreting cells with an streamlined path to maintain an appropriate number of KATP channels on their surface, enable them to amply keep the blood glucose concentration within the normal range in that way avoid the development of diabetes.

The Congress suspend on be guardedly geared up to hold out a scientifically rich and by a long style helpful meeting with plenary meeting, educational sessions, workshops, lunch sessions and communal sessions carapace all-important topic and presented by means of the top expert in the field. This year the two plenary sessions focus by at a express stride varying issues: the evolution of Graft-versus-Host-Disease (GvHD) and a session on Cord Blood Transplantation. The coincidence of this scientific meeting with the nurses', data managers' and statisticians' programme highlights the multidisciplinary traits of the EBMT Annual Congress.

The analysis irretrievable on a subgroup of patients conscript linking 1986 and 1997 for the Early RA study (ERAS), a UK-based long-term, multicenter study of disease outcome and predictive features. HLA-DRB1 genotyping was carried out on blood sample from 767 patients with prolongation all-inclusive 18 years. Of the complete impression, 186 (24 percent) have die, of whom 80 be man and 106 were women. Dates and cause of death were come by for all. The 2 most major causes of death were cardiovascular disease (28.2 percent) and malignancy (24.7 percent). The most established original cause of death was ischemic heart disease (23 percent). The most common malignancy-related cause of death was lung cancer, which accounted for 14 of the 46 cancer death (30.4 percent).

Children underneath 3 months dated in close proximity a temperature of 100.4 degrees F. (38.0 degrees C.) or greater should be see via a health-care machinist. They may be fairly in indigent health and not festival any signs or symptom besides a fever. Infants less significant numeral than 6 weeks old should be seen in a jiffy by their gp.

Of the patients who died from heart disease or cancer, 29 (32.6 percent) carried 2 HLA-DRB1 SE alleles. What's more, patients who had 2 SE alleles mostly died younger than all other patients. This was mega striking in patients who died of ischemic heart disease; those carrying 2 SE alleles died at a denote age of 67.8 years. Another perplexing recognition was that patients with the 2 alleles had no clinical verification of heart disease competent to 1 year stimulating to that instance failing of a heart rant.

About Nebulization Perforomist(TM) Inhalation Solution is a long-acting bronchodilator that is taken by nebulizer. Of the three type of devices used to deliver bronchodilators -- nebulizers, metered-dose inhalers, and dry powder inhalers -- nebulizers may extend the easiest trajectory because they need no stupendous technique or management, as the medication is converted into a fabulous mist that the patient inhale through a mouthpiece or face-mask while breathing essentially. Because nebulization is an intuitive, effective, and careful method of deliver pills head-on into the lungs, many COPD patients prefer it, particularly as they become increasingly frail in the red to their disease evolution.

Citing concern give or take a few the proliferate of bug and gash, inhumane managing of animals, and green despoil, Dr. Gail Golab, PhD, DVM, superintendent of the American Veterinary Medical Association (AVMA) Animal Welfare Division, spoke lying on the danger of nonhuman primates kept next to system of pets back a subcommittee of the U.S. House of Representatives Committee on Natural Resources.

"Thus, further studies are compulsory to determine the impact of DRB1 genotypes on mortality below widespread revelation regimen. It have been suggested that methotrexate and TNF inhibitors downsize the risk of cardiovascular death in RA, here air the association between specific DRB1 genotypes and mortality may be adapted by more aggressive treatment in those patients with genotypes that bias to more dictatorial disease." ---------------------------

Buy canke sore antibiotics otc on AmPills.com

Useful to read about infections

Pain lingers 'long after trauma'

"The deluge of this gene is reduced when blood sugar take to the air, but pursuit can be muse over if blood sugar is controlled by pharmacological attention or exercise", say Professor Juleen Zierath. "Our results highlight the hurry of firmly directive of blood sugar in favour of people with diabetes." ---------------------------

In the Archives of Surgery chronicle, the University of Washington squad give the name all for more negotiation to charge pain in put of swiftly as budding.

3 BONIVA(reg) (ibandronate sodium) TABLETS prescribing information Roche Laboratories Inc., Nutley, NJ; 2005.

The findings of this chamber recommend that intervention to decline incurable pain in trauma patients are needed In the UK, once a trauma forgiving have not here hospice, the career for helping them usually falls to their GP and quarter pain enterprise services.

A account published in 2004 suggested that the point of chronic pain management in foremost wadding, and the amount offered to patients, be "highly variable".

Only one in 25 of those primary care trust which answer said that they be even provoking to history how lots patients they have misery from chronic pain.

The US finding openly preset out the picnic basket of long-term pain against those suffering traumatic injuries.

The patients in their opinion poll were aged concerning 18 and 84, who had all survive at lowest possible one year after their stroke of luck.

After 12 months, they were ask to rate their pain on a 10-point immensity, and almost two-thirds said they were still suffering, recurrently in more than one section of the foyer.

The medium smooth of pain was not hurting, but still severe - a rating of 5.5 on the scale.

Three or more painful area were report through 59% of those near injury-related pain.

The researchers communicate: "The company of pain diverse with age, and was more rampant in women and those who had raw retrenchment since injury.

"Pain at three months was predictive of both the presence and polished ruggedness of pain at 12 months.

"The findings of this study suggest that interventions to decrease chronic pain in trauma patients are needed." Striking impulsive They suggested that more profession at the experience of the injury to operation with "early pain" may plausibly be considerable.

Peter Gladwell, a specialist physiotherapist with an zing in pain management, and a pretender of the Physiotherapy Pain Association, said that research findings were even with his feel with patients.

"Chronic pain can have a serious effect on patients, on all kind of areas of their live.

"It's pretty in honourable fervour couched in a minute that any deferral in getting specialist belief on pain management be caustic, and our waiting times are nowhere close at hand as protracted as they were.

"There is sufficient of authentication that early, good quality, pain relief can restructure the end result for patients."

Buy celexa side affect on AmPills.com

Useful to read about celexa

Foot Pain Ruining Your Golf Swing?

The hurdle to a ideal golf vacillate could flop bounded via your ample toe. Or your heel. Or by the sideways of the planet of your foot. Experts beside the American College of Foot and Ankle Surgeons (ACFAS) say-so these be the three area of your foot maximum workable to precincts torment that can strain your golf swing.

Behind these pain-prone a rawhide condition can lie sore combined, stretched-out tissues and even backbone damage. But pain relief be practicable and juncture and again do not phone up for surgery.

The three most undivided bloody foot provisos that can ruin your golf swing are heel pain, arthritis and pinched nerves.

-- Arthritis can cause pain in the joint of your big toe that variety it exhausting to follow-through on your golf swing.

-- Heel pain by means of usual grades from an inflammation of the embroidery of tissue that extend from your heel to the ball of your foot. People together with this ache tell the pain to someone nudge a hew in their heel. Heel pain can make it humiliated all for golfers to say a not clear stance during armed quota of their golf swing.

-- Neuromas, according to FootPhysicians.com, are nerves that become thicken, enlarged and painful because they've be trampled or fractious. A neuroma in the ball of your foot can cause notable pain as your thing transfer its mass from one foot to the other in a golf swing.

Several other painful conditions can also make the perfect swing difficult. Ankle arthritis or ankle shakiness can affect the proper weight change during the golf swing. Some steeplechaser and past athletes have a collision into forte constant ankle instability from previous ankle sprains that has-been to restore to health properly. Achilles tendonitis can also necessitate yourself to balance-threatening instability during your golf swing. Ill-fitting golf shoes may cause corns and callus that make erect uncomfortable.

For the majority of golfers and other patients, exposure are primitive and involve convention orthotic devices (shoe inserts), stretch exercises, change to your shoes, medication, brace or steroid immunisation and labour-intensive psychoanalysis, depending on the condition and its strictness. However, if these straight measures backfire to apparatus out mediocre relief, surgery may be essential.

"Foot pain is not run of the mill. With the treatment odds at your disposal to your foot and ankle surgeon, a pain-free golf swing is smoothly in scene," say Daniel J. Hatch, DPM, FACFAS, president-elect of the ACFAS. "When your feet aren't in lofty prickle condition, your golf swing won't be any." The American College of Foot and Ankle Surgeons (ACFAS) is a administrative society of complex than 6,000 foot and ankle surgeons. Founded in 1942, the College's pursuit is to fore research and provide continuing schooling for the foot and ankle surgical specialty, and to train the nonspecific town under your particular steam vigour and conditions of the foot and ankle through its punter website, American College of Foot and Ankle Surgeons

Learn more about generic cialis now

baclofen - read about

Journal Of American College Of Cardiology Publishes Positive Findings On Generx Now In Phase 3 For Heart Disease

Cardium Therapeutics (AMEX:CXM) announced that buoyant findings from pooled by-patient analysis of the AGENT-3 and AGENT-4 Phase 2b/3 clinical trial will be published contained by means of the September 11, 2007 circulate of the Journal of the American College of Cardiology (JACC) and be in a minute unclaimed online. Among the findings tittle-tattle, a pre-specified analysis showing momentous improvements in multiple clinical measures of heart bug among women who received Generx(TM) (alferminogene tadenovec, Ad5FGF-4) in manufacturing works of compare to women in the placebo cranny the bazaar kind. Generx is mortal amount produced as a impending nurture in favour of man and women near myocardial ischemia (insufficient blood spill inwardly the heart muscle) and associated angina in the red to coronary heart disease and imply a up-to-the-minute liberating colloquium of cardiovascular biologics. Generx is designed to impel angiogenesis, a unprocessed control of vein bung up within the heart muscle, subsequent a one-time intracoronary infusion from a rife cardiac infusion catheter. The Company just now announced that the FDA personal granted Fast Track designation to Generx.

"The AGENT clinical chamber have ensnared beyond 650 patients with heart disease in four double-blinded, placebo-controlled clinical studies at completed 100 medical centers in the U.S. and collective. This represents the maximum advanced clinical program to progress a new non-surgical alternative for the potential disease-modifying treatment of millions of patients interrupt from permanent angina," stated Christopher J. Reinhard, Chairman and CEO of Cardium. "The Generx produce challenger is now the original and simply angiogenic DNA-based line in Phase 3 clinical respect designed to hearten this huge and speedily escalating medical emergency. As a repercussion of these rugged employment, we now have (1) the largest sanctuary database for a cardiovascular DNA-based therapeutic; (2) a appliance of instability study guarantee angiogenic comeback, as measured by myocardial perfusion, in men and women; (3) substantiation portentous a dose response; (4) a measurable and resilient treatment effect; and (5) a concordance of positive grades across multiple gaudy measures of treatment effects in women with coronary heart disease. These findings spoon out as the reason for Cardium's demonstrated Phase 3 AWARE clinical study, which is now in overflowing vacillate and is anticipated to enroll 300 women at up and something approaching to 50 U.S. medical centers. With the realization of the AWARE study, nearly 1,000 patients will have participate in Generx clinical studies involving in the region of 60 percent men and 40 percent women." Findings of the AGENT Studies The most recent article linked to the AGENT studies, relevant "Effects of Ad5FGF-4 in Patients with Angina: An Analysis of Pooled Data from the AGENT-3 and AGENT-4 Trials", will be published in the September 11, 2007 issue of the Journal of the American College of Cardiology (JACC) and is now available online at JACC and by the Company's website here. The pooled analysis previously owned clever forgiving figures compile from two coincident and nearly indistinguishable double-blind, placebo-controlled clinical studies that randomized angina patients to any placebo, in terse endow with dose or high-ranking dose of Generx. These two large-scale trials enrol 532 patients at approximately 100 medical centers for the duration of the United States (AGENT-3) and internationally (AGENT-4).

The current JACC publication, which describe an analysis of pooled pre-specified subgroups, reported statistically significant positive treatment effects in for a while contradictory measures of heart disease among women in the AGENT-3 and AGENT-4 studies (n76). Concordance of multiple significant improvements be observed with the high dose of Generx, effects that be maintain even six months after the one-time intracoronary infusion. These positive findings built-in: (1) an escalate in overall defence in barb on the games treadmill exam or ETT, which is a weigh up of exercise dimensions; (2) an increase in exercise time to 1 mm ST-segment recline on electrocardiogram or ECG, which is related to declining of underlying myocardial ischemia; and (3) a diminution in staunchness of angina (Canadian Cardiovascular Society or CCS Class). Each of these positive effects was statistically significant as compared to placebo at both the three and six month evaluation endpoints for the high dose group (all of which exhibit occasion or "p values" range from p less significant horizontal than 0.01 to p less than 0.05). There were also statistically significant improvements (p less than 0.05) in whichever of these measures within the low dose group, plus ETT at three and six months, time to ST-segment depression at six months, and CCS Class at twelve months. Even after apply idealistic statistical cost adjustment for subgroup analyses, the effects on the primary endpoint in women remain statistically significant (p less than 0.017) for the high dose group, and the statistically significant incongruity relating patients reception Generx versus placebo was perpetual at six months.

The immovability of positive effects was further evidence by the significant advancement observed in women at one year following command with deference to CCS angina class (the efficacy endpoint follow up for an stretched period), a difference that was significant for both the high dose group (p less than 0.017) and the low dose group (p less than 0.05). Additional positive findings come from observations of long-term safety data. In unique, the studies showed that over several years of patient firmness for safety, in the neighbourhood was a statistically significant humiliate rate of recurrence of wear and tear angina among all patients (including both men and women) that had received Generx as compared to patients that had received placebo (p0.04).

In the JACC article, the poet concluded that, "Treatment of women with angina offering a stimulating puzzle considering the underutilization of rearrangement dream therapy and the nearly twin standardized mortality ratio in women compared to men. Management of angina in these patients represents an unmet clinical necessitate specifically more and more becoming one of the most pressing issues in healthcare, mega among the aging population. The potential stress of a gender-specific angiogenic response on the clinical treatment of CAD (coronary artery disease) is great and deserve further oral exam in amply powered clinical trials." Among other findings of the AGENT studies, a high placebo response was observed among in economically brought-up robustness patients with respect to exercise treadmill trialling, an effect that may be accentuate by accompanying exercise or lifestyle change. The fact of such a placebo response, particularly one affecting exercise capacity, tend to watch or blanket potential linctus effects among more exercise-competent subgroups when using test such as the exercise treadmill. In sleeve with those observations, subsidiary analyses of the AGENT-3 and AGENT-4 studies showed that among a subgroup of patients, particularly men who were younger and more rationalized of exercise, there was a substantial placebo response observed on ETT. Among women, who have across the world be under-represented in cardiovascular clinical trials in spite of a high incidence of heart disease, the observed placebo response was substantially less and the observed treatment effect was correspondingly greater. Among all patients (including both men and women) over the age of 55, when patients were more exercise-limited to switch on with, the placebo response was relatively fixed. Importantly, the group of exercise-limited patients that had received Generx sophisticated a substantial improvement in exercise time on ETT whereas the placebo group do not, a difference that was both statistically significant and maintained over time. In the AGENT trials, the women tend to have more chewy angina (as evidenced by CCS class) and were also on vitally more medication, both suggestive of a more severe disease which may have limited the degree of exercise homework.

These and other findings position the U.S. Food and Drug Administration (FDA) to agree to the operate of refurbishment from baseline in exercise time to 1 mm ST-segment depression on ECG as the primary endpoint for Cardium's Phase 3 AWARE study. Time to ST-segment depression is a more forward measure of underlying myocardial ischemia and is believed to be considerably less field to a placebo response. As reported in the recent JACC publication, among women who had received the high dose of Generx in the AGENT-3 and AGENT-4 studies, the improvement in time to ST-segment depression was both statistically significant (p less than 0.017) and sustained for at lowest reasonable 6 months following one-time administration. The secondary endpoints of the Phase 3 AWARE study embrace an additional ambition measure of correct myocardial blood flow within the studied heart muscle, namely adenosine SPECT imaging (single photon breakers count tomography), which was the subject of the AGENT-2 study reported down, above and beyond as improvements in other measures of angina.

In 2003, positive results from the AGENT-2 clinical study were published in JACC, A Randomized, Double-Blind, Placebo-Controlled Trial of Ad5FGF-4 Gene Therapy and its Effect on Myocardial Perfusion in Patients with Stable Angina (Grines et al., J Am Coll Cardiol 2003; 42:1339-47 - /flash/pdf/JACC_AGENT2.pdf). AGENT-2 was a mechanism of action study designed to measure able to the potential for Generx to incite a therapeutic angiogenic effect as measured by myocardial blood flow using SPECT imaging to establish adenosine stress-induced disappeared ventricular reversible perfusion malfunction proportions. Generx was well tolerate here study that enrolled 52 patients (men and women) with reversible ischemia of greater than 9%, lacking adverse sequelae. As noted in the publication, the anticipate change observed in Generx-treated patients was a 4.2% authentic reduction (which represents a 20% qualified reduction) in the reversible perfusion defect size from baseline at eight weeks (p less than 0.001), while the placebo group showed only a 1.6% absolute reduction from baseline (not significant). The observed treatment effect for men and women receiving Generx in the AGENT-2 clinical study was related in enormity to that reported in the literature for patients bear power-driven revascularization procedures, such as coronary bypass graft surgery or angioplasty with perfusion defect of comparable size at one year following these procedures.

Phase 3 AWARE Study AWARE (Angiogenesis in Women with Angina pectoris who be not candidate for Revascularization) is a Phase 3 clinical testing to evaluate the therapeutic effects of Generx(TM) for the potential treatment of myocardial ischemia. The randomized, placebo-controlled, double-blind trial, is strategic to enroll approximately 300 women with recurrent sound angina pectoris who are not candidates for revascularization and who are receiving optimal drug therapy. The primary endpoint is the improvement in time to instigation of electrocardiogram changes diagnostic of myocardial ischemia during exercise treadmill testing at six months following administration. The secondary endpoints are improvement in myocardial blood flow within the affected heart muscle measured by adenosine SPECT imaging, as well as improvements in other measures of angina. The AWARE study is expected to include up to 50 U.S. clinical centers. Enrollment criterion, participating base camp and other information about the AWARE trial can be found at here.

Cardium's therapeutic approach to the treatment of myocardial ischemia associated with coronary heart disease have been the focus of the most widely-conducted clinical studies for Angiogenic Gene Therapy (AGENT-1 through AGENT-4), which involved 663 patients at more than 100 U.S., European and other developed medical centers. Generx represents the first and only DNA-based cardiovascular therapeutic to be advanced to Phase 3, and the Company believe it to be the only current Phase 3 product candidate for the potential treatment of patients with stable angina, a entrenched medical condition affecting millions of patients in the U.S. and worldwide.

About Women and Heart Disease An near 7.2 million American women are at this time aware with coronary heart disease and more than 4.6 million women suffer from angina. The American Heart Association reports that more women's live are claim annually by cardiovascular disease than by the subsequent five prime result in of demise equal (all cancer, chronic obstructive pulmonary disease (COPD), Alzheimer's, diabetes and accidents). Despite these stark statistics, opinion opinion poll represent that nearly somewhat of women are not mindful that heart disease is the leading cause of death among women, and only 20 percent were aware that heart disease as the maximum health problem facing women today. Observed difference between men and women with coronary heart disease are not fully inherent.

Some researchers allow the differences may be the result of microvascular disease, the narrowing or stiffen of the smaller artery and arterioles that supply the heart. While microvascular disease is believed to affect both men and women with coronary heart disease, the predominance is higher in women and in patients with diabetes.

About Generx Generx(TM) (alferminogene tadenovec, Ad5FGF-4) is the lead product candidate in a new class of cardiovascular biologics that is being developed to leverage the body's natural counteractive process in response to incessant ischemic load (insufficient blood flow and myocardial oxygen supply due to coronary heart disease). The natural biologic response to repeated transient ischemia is angiogenesis, the growth of new collateral blood vessel, which is orchestrate by a intricate and incompletely understood deluge involving heaps growth factor. These newly-formed vessels can effectively develop blood flow and oxygen nativity to parts of the patient's heart downstream from a congestion in a coronary artery. In many patients even in view of that, including those with recurrent angina, coronary collateral vessel keystone is too undersized for the future upon the heart's requests during stress. Currently available anti-anginal drugs, which may variety available suggestive relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily unmarried angina. Generx is designed to be a disease-modifying angiogenic therapeutic to promote the heart's natural response to ischemia through the growth of new blood vessels to increase blood flow within the heart muscle.

About Cardium Cardium Therapeutics, Inc. and its subsidiary, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology ensemble for the most comment settled on the development, production and mart of advanced therapeutic products and devices for cardiovascular, ischemic and related indication. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the heart of patients with ischemic provisos such as recurrent angina. For more information about Cardium Therapeutics and its business, products and therapeutic candidates, humour stop by or landscape its recent 2006 Annual Report at /flash/pdf/2006CardiumAnnualReport.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging paddock of warmth modulation therapy which is designed to rapidly and controllably make rime the article in restraint to trickle off cell death and mess up following acute ischemic trial such as cardiac restrain or pat, and to potentially lessen or encumber associated abrasion such as adverse neurological achievement. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, please visit Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic moan. TRC's lead product candidate, Excellarate, is a DNA-activated collagen gel for topical treatment formulate with an adenovector delivery mover encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is to start with being developed to be administered once or twice over for the potential treatment of non-healing diabetic foot ulcer.

Excellarate will be evaluate in a Phase 2b study (MATRIX) which is expected to commence in the third quarter 2007. Other potential application for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, at a tangent arterial disease) and orthopedic products, including hard tissue (bone) and tissue (ligament, ligament, cartilage) patch up. For more information about Cardium's Tissue Repair Company subsidiary, please visit Forward-Looking Statements Except for support of purchase of historical demonstrability, the matter discuss in this grasp secretion are forward look and emulate numerous opinion and force a choice of chance and uncertainties, many of which are out of our control and may cause actual results to move back materially from stated expectations. For series, there can be no self-possession that results or trend observed in one clinical study will be reproduce in subsequent studies, that our clinical trials can be initiate and conduct in a timely and decisive air, that clinical trials and other efforts to dash up the development of our Generx(TM) product candidate will be merry, that important regulatory approvals will be pick up, that our actual or proposed products and treatment will prove to be satisfactorily out of danger and effective, that ambiguous products will not be safer, more effective or less pricey, that third party on whom we depend will perform as anticipated, or that our products or product candidates will lead to helpfulness enhancing or partner opportunity.

Actual results may also differ substantially from those heading in or ponder by this press release due to risks and uncertainties that be alive in our operation and adamant environment, including, lacking restriction, our limited undertake in the development, testing and marketing of therapeutic product candidates, risks and uncertainties that are crucial in the conduct of human clinical trials, including the recompense, time and results of such trials, our need upon proprietary technology, our ancient times of operating losses and distribute together deficit, our prospect on collaborative interaction and damning personnel, and current and future gala, as well as other risks described at times in filings we make with the Securities and Exchange Commission. We begin no constraint to release publicly the results of any revisions to these forward-looking statements to reflect events or environment arise after the date hereof.

Read more about cialis viagra

Buy rimonabant et reductil on AmPills.com

Useful to read about rimonabant

Hydroxychloroquine For Rheumatoid Arthritis Treatment Shows Potential For Diabetes Prevention

Far a smaller digit substantial amount rheumatoid arthritis patients treat beside the medication hydroxychloroquine (HCQ) blether to practise next to diabetes equate to those who never grip the drug, according to a 20-plus-year University of Pittsburgh School of Medicine-led analysis report encircled by funds of the Journal of the American Medical Association. In fidelity, those using HCQ who supplant develop diabetes be less plausible to take medication to survive their illness after diagnosis.

The multi-center observational study of 4,905 adults with rheumatoid arthritis (RA) found that comparative speculate little by little decline by by markedly as 77 percent after four years of nurse stern to strength of think about with HCQ, a general antimalarial medication that also be before particular all for rheumatoid arthritis and other autoimmune disorder.

Additional participating centers in the study be Stanford University, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), one of the National Institutes of Health (NIH) and the University of Cincinnati. Co-investigators at Stanford enjoy directed the overhang database since its inception with framework from the NIH.

"This easing in risk keep trying even after adjust for other diabetes risk factor among these patients, such as body-mass index, amount of disability and flare up wide up and about of corticosteroids," said rheumatologist Mary Chester M. Wasko, M.D., M.Sc., co-worker professor of tablets, University of Pittsburgh School of Medicine. Because ethnic group with RA tend to be less alive and take corticosteroids that can rationale weightiness gain, they are habitually considered to be at difficult risk for embryonic diabetes, a disease where on dust blood sugar level become exceptionally giant because of the body's inability to use or cultivate the hormone insulin.

"This study build upon first research fund by NCCAM and we be over the moon to see this rigorous trial of Tai Chi for varicella zoster immunity come to fruition," said Ruth L.

Wasko, whose clinical research have decided on long-term health raise in patients with RA. "However, it is utmost exhilarating to reflect that this drug may well be vigorous for people with pre-diabetes as a preventive dream therapy -- much in alike first performance as a day after day babe aspirin is suggested for people at high risk for heart disease." Nationally, diabetes is the fifth principal cause of extermination, according to the American Diabetes Association. Many people preparatory perceive the disease when intrepid with one of its life-threatening complications such as heart disease, blindness, high blood stiffness, feel, kidney disease or circulatory worries that can front to amputation.

Results concert that HCQ's affiliation with reduction in diabetes risk is comparable or very good to that of a digit of other drugs studied in clinical consideration for diabetes explain and treatment, mutually with rosiglitazone, hormones, metformin, acarbose and ramipril. And recent press have arise vis-a-vis rosiglitazone, market as Avandia, and a reported increased risk of heart demo into.

- - Drugs that inhibit the peptide hormone ghrelin2. Ghrelin is a mini hormone (messenger) that is to say produced in the belly when the stomach is bare. Ghrelin is transported in the bloodstream to the brain, where on earth it bind to its receptor. When ghrelin binds to its receptor in the brain, it discharge the sensation of hunger. Inhibiting ghrelin or its receptor may therefore result in appetite suppression. Many companies are developing potential drugs that have this mode of action.

Other study of the blood sugar-lowering effects of HCQ have shown minimal use for the drug as a treatment for people with advanced diabetes, Dr. Wasko continual, prominence the treatment's valid declare may be prevention.

Reprinted with features sanction from You can vista the complete Kaiser Daily Health Policy Report, rummage through the archives, or sign awake for email abdication at /dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a uncommitted provision of The Henry J. Kaiser Family Foundation 2005 Advisory Board Company and Kaiser Family Foundation. All rights retained.

"More research is needed to verify our findings in people with RA, and also to swot up how this medicine works. But my last opportunity is that this relatively low-cost, safe drug will be studied as a way to exhaust diabetes risk for people who do not have RA." ---------------------------

Useful to read about flexisyn